Abstract:Major depressive disorder (MDD) is one of the most disabling psychiatric disorders. Approximately one‐third of the patients with MDD are treatment resistant to the current antidepressants. There is also a significant therapeutic time lag of weeks to months. Furthermore, depression in patients with bipolar disorder (BD) is typically poorly responsive to antidepressants. Therefore, there exists an unmet medical need for rapidly acting antidepressants with beneficial effects in treatment‐resistant patients with MDD or BD. Accumulating evidence suggests that the N‐methyl‐D‐aspartate receptor (NMDAR) antagonist ketamine produces rapid and sustained antidepressant effects in treatment‐resistant patients with MDD or BD. Ketamine is a racemic mixture comprising equal parts of (R)‐ketamine (or arketamine) and (S)‐ketamine (or esketamine). Because (S)‐ketamine has higher affinity for NMDAR than (R)‐ketamine, esketamine was developed as an antidepressant. On March 5, 2019, esketamine nasal spray has been approved by the US Food Drug Administration. However, preclinical data suggest that (R)‐ketamine exerts greater potency and longer‐lasting antidepressant effects than (S)‐ketamine in animal models of depression and that (R)‐ketamine has less detrimental side effects than (R,S)‐ketamine or (S)‐ketamine. In this article, the author reviews the historical overview of the antidepressant actions of enantiomers of ketamine and its major metabolites norketamine and hydroxynorketamine. Furthermore, the author discussed the other potential rapid‐acting antidepressant candidates [i.e., NMDAR antagonists and modulators, low‐voltage‐sensitive T‐type calcium channel inhibitor, potassium channel Kir4.1 inhibitor, negative modulators of γ‐aminobutyric acid, type A (GABAA) receptors] to compare them with ketamine. Moreover, the molecular and cellular mechanisms of ketamine's antidepressant effects have been discussed.This article is protected by copyright. All rights reserved.

A Multifunctional Nanocarrier System for Highly Efficient and Targeted Delivery of Ketamine to NMDAR sites for Improved Treatment of Depression

Ketamine Exerts Its Sustained Antidepressant Effects Via Cell-Type-specific Regulation of Kcnq2.

NMDAR inhibition-independent antidepressant actions of ketamine metabolites

NMDA receptors as therapeutic targets for depression treatment: Evidence from clinical to basic research

Design, Synthesis and Biological Evaluation of Novel Ketamine Derivatives as NMDAR Antagonists

Antidepressant effects of ketamine and the roles of AMPA glutamate receptors and other mechanisms beyond NMDA receptor antagonism

Rapid‐acting antidepressant ketamine, its metabolites and other candidates: A historical overview and future perspective

Transferrin-modified Carboxymethyl Chitosan-Chitosan Nanoparticles As an Efficient Delivery Carrier for Targeted Therapy of Depression

Microglial ERK-NRBP1-CREB-BDNF signaling in sustained antidepressant actions of (R)-ketamine

Exploring the multifaceted potential of (R)-ketamine beyond antidepressant applications

Research Progress on NMDA Receptor Enhancement Drugs for the Treatment of Depressive Disorder

Repurposing Ketamine in the Therapy of Depression and Depression-Related Disorders: Recent Advances and Future Potential

Proteomic Study Reveals The Involvement Of Energy Metabolism In The Fast Antidepressant Effect Of (2r, 6r)-Hydroxy Norketamine

Nanocarrier drug delivery system: promising platform for targeted depression therapy

Combining bioinformatics, network pharmacology and artificial intelligence to predict the target genes of S-ketamine for treating major depressive disorder

Molecular mechanisms of the rapid-acting and long-lasting antidepressant actions of (R)-ketamine

NMDA antagonist treatment of depression

Ketamine reverses chronic corticosterone-induced behavioral deficits and hippocampal synaptic dysfunction by regulating eIF4E/BDNF signaling

Effects of ketamine on circadian rhythm and synaptic homeostasis in patients with treatment-resistant depression: A protocol for mechanistic studies of its rapid and sustained antidepressant actions in humans

Sustained Antidepressant Effect of Ketamine Through NMDAR Trapping in the LHb

Advancing past ketamine: emerging glutamatergic compounds for the treatment of depression